Friday - April 19, 2024

Category Archives: Financial Market

Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, Amgen, Astellas, Seagen

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action … Continue reading →

Gastrointestinal Stromal Tumor Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Daiichi Sankyo, Novartis, Takeda, Plexxikon

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 28+ pipeline drugs in the Gastrointestinal Stromal Tumor therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), … Continue reading →

Marginal Zone Lymphoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Adicet Bio, ArQule, Merck, BeiGene, Bayer

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Marginal Zone Lymphoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), … Continue reading →

B-Cell Lymphomas Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Oncternal, ZAI Lab, Pfizer, SystImmune, Vincerx, InnoCare

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 160+ key pharma and biotech companies are working on 170+ pipeline drugs in the B-Cell Lymphomas therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and … Continue reading →

Epilepsy Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | LifeSplice, Neuroene, Xenon Pharma, Epygenix, Addex Pharma, Cevevel,

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 90+ pipeline drugs in the Epilepsy therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule … Continue reading →

Advanced Endometrial Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Incyte, Byondis, Genentech, Zymeworks, Pfizer

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Advanced Endometrial Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), … Continue reading →

Cirrhosis Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Lipocine, Galectin, Pharmicell, BioVie, Gilead, Novartis, Genfit

Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Cirrhosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule … Continue reading →

“Intelligent Bio Solutions Inc. (NASDAQ: INBS) Innovative Drug Screening Technology Sparks Excitement at Global Mining Industry Conference” – CLLS, DTIL, OCUL

Intelligent Bio Solutions Inc. (NASDAQ: INBS) showcased their “Innovative Drug Screening Technology ” at the International Mining and Resources Conference (IMARC) in Sydney, Australia this week. The company’s innovative sweat-based drug screening solution garnered significant interest at the conference from … Continue reading →